Back to catalogue
COIL

Coiled Therapeutics PLC

Health Care First-pass screen £32m
350/1000 Overall fit
AI beneficiary 35% 40
Operating leverage 25% 37
Valuation 25% 30
Downside protection 15% 27

First-pass take

Pre-revenue clinical-stage biotech with Phase I oncology asset; indirect AI exposure via parent company A2A's computational drug discovery platform. Transformation hinges on completing Coiled USA acquisition. Near-term liquidity crisis: £330k/6mo cash burn against £182k balance and net debt position.

Flags

clinical-stageloss-makingpre-revenuecash-burngoing-concernnet-debtacquisition-dependent